SRPT - Sarepta Therapeutics President & CEO Makes $2.00M Stock Purchase | Benzinga
Douglas S Ingram, President & CEO at Sarepta Therapeutics (NASDAQ:SRPT), reported a large insider buy on November 6, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Ingram purchased 25,225 shares of Sarepta Therapeutics. The total transaction amounted to $2,001,799.
Sarepta Therapeutics shares are trading up 3.87% at $81.03 at the time of this writing on Monday morning.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Why Insider Transactions Are Important
Insider transactions shouldn't be used primarily to make an investing decision, ...